Could aid efforts to find treatments for Alzheimer’s, other diseases
Researchers at Washington University School of Medicine in St. Louis have found a new druggable pathway that potentially could be used to help prevent Alzheimer’s dementia.
Amyloid beta accumulation in the brain is the first step in the development of Alzheimer’s dementia. Scientists have poured countless hours and millions of dollars into finding ways to clear amyloid away before cognitive symptoms arise, with largely disappointing results.
In this study, published Aug. 24 in the journal Brain, researchers found a way to increase clearance of waste products from the brains of mice by ramping up a genetic quirk known as readthrough. This same strategy also may be effective for other neurodegenerative diseases characterized by the buildup of toxic proteins, such as Parkinson’s disease, the researchers said.
Every once in a while, the brain protein aquaporin 4 is synthesized with an extra little tail on the end. At first, Darshan Sapkota, PhD — who led this study while a postdoctoral researcher at Washington University but is now an assistant professor of biological sciences at the University of Texas, Dallas — thought this tail represented nothing more than an occasional failure of quality control in the protein-manufacturing process.
“We were studying this very wonky basic science question — ‘How do proteins get made?’ — and we noticed this funny thing,” said senior author Joseph D. Dougherty, PhD, a Washington University professor of genetics and of psychiatry, and Sapkota’s former mentor. “Sometimes the protein-synthesizing machinery blew right through the stop sign at the end and made this extra bit on the end of aquaporin 4. At first, we thought it couldn’t possibly be relevant. But then we looked at the gene sequence, and it was conserved across species. And it had this really striking pattern in the brain: It was only in structures that are important for waste clearance. So that’s when we got excited.”
Scientists already knew that the cell’s protein-building machinery occasionally fails to stop where it should. When the machinery doesn’t stop — a phenomenon known as readthrough — it creates extended forms of proteins that sometimes function differently than the regular forms.
Sapkota and Dougherty created tools to see whether the long form of aquaporin 4 behaved differently in the brain than the regular form. They found the long form — but not the short one — in the so-called endfeet of astrocytes. Astrocytes are a kind of support cell that help maintain the barrier between the brain and the rest of the body. Their endfeet wrap around tiny blood vessels in the brain and help regulate blood flow. Astrocytic endfeet are the perfect place to be if your job is to keep the brain free of unwanted proteins by flushing waste out of the brain and into the bloodstream, where it can be carried away and disposed of.
Thinking that increasing the amount of long aquaporin 4 might increase waste clearance, Sapkota screened 2,560 compounds for the ability to increase readthrough of the aquaporin 4 gene. He found two: apigenin, a dietary flavone found in chamomile, parsley, onions and other edible plants; and sulphaquinoxaline, a veterinary antibiotic used in the meat and poultry industries.
Sapkota and Dougherty teamed up with Alzheimer’s researchers and co-authors John Cirrito, PhD, an associate professor of neurology, and Carla Yuede, PhD, an associate professor of psychiatry, of neurology and of neuroscience, to figure out the relationship between long aquaporin 4 and amyloid beta clearance.
The researchers studied mice genetically engineered to have high levels of amyloid in their brains. They treated the mice with apigenin; sulphaquinoxaline; an inert liquid; or a placebo compound that has no effect on readthrough. Mice treated with either apigenin or sulphaquinoxaline cleared amyloid beta significantly faster than those treated with either of the two inactive substances.
“There’s a lot of data that says reducing amyloid levels by just 20% to 25% stops amyloid buildup, at least in mice, and the effects we saw were in that ballpark,” Cirrito said. “That tells me that this could be a novel approach to treating Alzheimer’s and other neurodegenerative diseases that involve protein aggregation in the brain. There’s nothing that says this process is specific for amyloid beta. It may be enhancing, say, alpha-synuclein clearance, too, which could benefit people with Parkinson’s disease.”
Sulphaquinoxaline is not safe for use in people. Apigenin is available as a dietary supplement, but it’s not known how much gets into the brain, and Cirrito cautions against consuming large amounts of apigenin in an attempt to stave off Alzheimer’s. The researchers are working on finding better drugs that influence the production of the long form of aquaporin 4, testing several derivatives of sulphaquinoxaline and additional compounds.
“We’re looking for something that could be quickly translated into the clinic,” Sapkota said. “Just knowing that it’s targetable at all by a drug is a helpful hint that there’s going to be something out there we can use.”
Original Article: Study points to new approach to clearing toxic waste from brain
More from: Washington University School of Medicine
The Latest on: Alzheimer’s dementia
- Distressing Dreams and Dementia; Global COVID-Brain Study; Biogen Resolves Claimson September 27, 2022 at 12:33 pm
Distressing dreams predicted cognitive decline and all-cause dementia in middle-aged and older adults without cognitive impairment or Parkinson's disease, especially men. ( eClinicalMedicine) A life ...
- Fasting-mimicking diet reduces signs of dementia in miceon September 27, 2022 at 12:18 pm
Cycles of a diet that mimics fasting appear to reduce signs of Alzheimer's in mice genetically engineered to develop the illness, according to a new USC Leonard Davis School of Gerontology-led study.
- New model of Alzheimer's as an autoimmune diseaseon September 27, 2022 at 10:46 am
Scientists have proposed a new mechanistic model (AD2) for Alzheimer's, looking at it not as a brain disease, but as a chronic autoimmune condition that attacks the brain.
- DAVOS ALZHEIMERS COLLABORATIVE FEATURED ON THE TODAY SHOW DURING WORLD ALZHEIMER’S AND HISPANIC HERITAGE MONTHon September 27, 2022 at 10:11 am
Initiative Brings Inclusive Research to Community with High Incidence of Alzheimer’sWashington, DC, Sept. 27, 2022 (GLOBE NEWSWIRE) -- The Davos Alzheimer’s Collaborative (DAC), the organization ...
- Alzheimer’s Association Walk to end Alzheimer’s to take place in Harrisburgon September 27, 2022 at 9:34 am
Harrisburg residents are invited by the Alzheimer’s Association to join the fight to end Alzheimer’s by participating in the Alzheimer’s ...
- Steps to take following a dementia diagnosis, especially if you live aloneon September 27, 2022 at 9:32 am
Here are resources and suggestions to help navigate a dementia diagnosis, including help for those who live independently ...
- Researchers identify new model of Alzheimer's as an autoimmune diseaseon September 27, 2022 at 4:21 am
Scientists at the Krembil Brain Institute, part of the University Health Network, have proposed a new mechanistic model (AD2) for Alzheimer's, looking at it not as a brain disease, but as a chronic ...
- Alzheimer's walk met goal by raising $65,000 Saturday during event at Peet Junior Highon September 27, 2022 at 3:00 am
Participants at Saturday’s Walk to End Alzheimer’s helped reach the goal of raising $65,000 to fund dementia care, support and research through the Alzheimer’s Association.
- Pilot program launches in Sacramento to make sure Alzheimer's patients aren't forgottenon September 27, 2022 at 1:12 am
A new pilot program called Blue Zone is aimed at improving the quality of life for those suffering from dementia. These zones will be at designated as some local qualifying venues.
- Alzheimer’s is the most common form of dementiaon September 26, 2022 at 8:00 pm
We know that when we store a memory, we are storing information. But what that information is and how long we retain it determines what type of memory it is.
via Bing News
The Latest on: Alzheimer’s dementia
via Google News